UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Total received in grants · trailing 12 months
$28M
$0for every U.S. household÷ 131M U.S. households
In perspective
0.0%of all $162.9B in tracked grants
5separate grants, trailing 12 months
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION has received $28M across 5 federal grants of $1M or more on record.
Data as of July 24, 2026. Source: USAspending.gov, prime contract awards $1M+. Federal spending data lags and has known gaps. This is not a real-time or complete record.
Grants by agency
Where this recipient’s grant dollars come from.
All grant awards
Swipe to see description and amount →
| Agency | Description | Amount |
|---|---|---|
| Department of Justice | ABCD SOCIAL DEVELOPMENT (ABCD-SD) | $12,361,120 |
| Department of Health and Human Services | UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE - PROJECT SUMMARY THE UNIVERSITY OF PITTSBURGH (PITT) CLINICAL TRANSLATIONAL SCIENCE INSTITUTE (CTSI) WILL BUILD ON THE SUCCESS SINCE ITS FOUNDING IN 2006 OF SUPPORTING TRANSLATIONAL RESEARCH TO NOW CONDUCT RIGOROUS AND IMPACTFUL TRANSLATIONAL SCIENCE, IDENTIFYING GENERALIZABLE METHODS AND STRATEGIES THAT ACCELERATE TRANSLATIONAL RESEARCH. OUR STRATEGY IS FOR CTSI TO OPERATE AS A LEARNING RESEARCH SYSTEM THAT USES TRANSLATIONAL SCIENCE PRINCIPLES AND FRAMEWORKS TO OVERCOME BARRIERS TO THE PLANNING, CONDUCT, DISSEMINATION, OR IMPLEMENTATION OF TRANSLATIONAL RESEARCH. OUR LEARNING RESEARCH SYSTEM WILL LEVERAGE THE >700 SERVICE, CONSULTATION, AND RESOURCE REQUESTS WE RECEIVE EACH YEAR FROM PITT INVESTIGATORS TO IDENTIFY COMMON RESEARCH OBSTACLES TOWARD THE DEVELOPMENT, TESTING, AND DISSEMINATION OF GENERALIZABLE SOLUTIONS. SPECIFICALLY, WE WILL: 1) APPLY TRANSLATIONAL SCIENCE THROUGH OUR LEARNING RESEARCH SYSTEM TO SYSTEMATICALLY IMPROVE TRANSLATIONAL RESEARCH TOOLS, RESOURCES, AND EFFICIENCY; 2) CONNECT INVESTIGATORS WITH COMMUNITIES, PATIENTS, CLINICIANS, AND POLICYMAKERS TO CREATE WELL-RESOURCED AND SKILLED TEAMS WHO DELIVER IMPACTFUL TRANSLATIONAL RESEARCH; AND 3) SYSTEMATICALLY STUDY THE IMPACT OF RAPID ADVANCES IN DATA SCIENCE AND ARTIFICIAL INTELLIGENCE ON TRANSLATIONAL RESEARCH AND TRANSLATIONAL SCIENCE. WE WILL GATHER QUANTITATIVE AND QUALITATIVE DATA ON GAPS AND OPPORTUNITIES IN TRANSLATIONAL RESEARCH AND THEN CREATE AND TEST NOVEL METHODS TO ENHANCE RESEARCH EFFICIENCY, QUALITY, INNOVATION, RIGOR, AND REPRODUCIBILITY. OUR METHODS WILL INCLUDE CREATING AND REFINING AN ONTOLOGY TO CHARACTERIZE RESEARCH BARRIERS AND DEVELOPING SCALABLE MEASURES OF RESEARCH OUTPUT AND IMPACT. WITHIN THIS FRAMEWORK, WE WILL IDEATE AND ITERATIVELY REFINE SOLUTIONS THAT, IF EFFECTIVE, WE WILL DISSEMINATE BACK TO OUR INVESTIGATORS AND BEYOND. WE WILL WORK TO SEAMLESSLY INTEGRATE RESEARCH IN THE CONTEXT OF CLINICAL CARE THROUGH RESEARCH TRAINING FOR CLINICIANS, SUPPORT PRACTICE-BASED RESEARCH NETWORKS, AND EARN THE TRUST OF PATIENTS AND THE BROADER COMMUNITY BY LISTENING, ENGAGING, AND ELEVATING THEIR ROLE AS MEMBERS OF THE RESEARCH TEAM. WE WILL ALSO PROMOTE STRONG AND SUSTAINABLE BIDIRECTIONAL RELATIONSHIPS WITH A WIDE RANGE OF STAKEHOLDER GROUPS AND EXAMINE NEW WAYS TO GATHER, TRAIN, AND SUSTAIN MULTIDISCIPLINARY TEAMS. WE WILL IDENTIFY HOW AND WHEN NEW DATA SCIENCE INNOVATIONS ARE ADOPTED, HOW THEY INFLUENCE THE EFFICIENCY AND RIGOR OF TRANSLATIONAL RESEARCH, AND HOW THEY ALTER THE INTERACTIONS BETWEEN INVESTIGATORS, INDIVIDUALS, PATIENTS AND CLINICIANS. WE WILL DEVELOP, DEMONSTRATE, AND DISSEMINATE METHODS FOR USING REAL-WORLD DATA TO ADVANCE RESEARCH AND GENERATE NEW KNOWLEDGE. WE WILL DEVELOP AND TEST ANALYTIC APPROACHES TO DETECT AND MITIGATE DATA- OR AI-GENERATED THREATS TO RIGOR OR GENERALIZABILITY AND OFFER TIMELY LEARNING MODULES THAT OPTIMIZE THE ABILITY OF OUR INVESTIGATORS TO LEVERAGE THE LATEST AI TOOLS AND RESOURCES. BUILDING ON TWO DECADES OF IMPACT, CTSI ACTIVITIES MOVING FORWARD WILL HELP INTEGRATE TRANSLATIONAL RESEARCH INTO THE CULTURE OF CLINICAL OPERATIONS, INCREASE TRUSTWORTHINESS AND PARTICIPATION IN ALL STUDIES, AND PURSUE TRANSLATIONAL SCIENCE WITH GOAL-DRIVEN INTENTIONALITY TO ENABLE THESE OUTCOMES. | $10,192,245 |
| Department of Energy | MECHANISM OF CO2 CAPTURE IN IONIC LIQUID COMPOSITE MATERIALS | $2,564,315 |
| Department of Health and Human Services | UNITED IMAGING UNEUROEXPLORER BRAIN PET/CT SCANNER - PROJECT SUMMARY/ABSTRACT THIS PROPOSAL REQUESTS FUNDS FOR A UNITED IMAGING UNEUROEXPLORER BRAIN PET/CT SCANNER TO SUPPORT A HIGHLY SUCCESSFUL POSITRON EMISSION TOMOGRAPHY (PET) RESEARCH PROGRAM AT THE UNIVERSITY OF PITTSBURGH. THIS VIBRANT RESEARCH PROGRAM PRESENTLY ENCOMPASSES 25 NIH-FUNDED NEUROIMAGING PROJECTS AS WELL AS SEVERAL FOUNDATION AND INDUSTRY SUPPORTED STUDIES LED BY INVESTIGATORS FROM 8 ACADEMIC DEPARTMENTS OF THE UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE. THE UNIVERSITY OF PITTSBURGH PET CENTER (UPPC) HAS BEEN OPERATIONAL SINCE 1992 AND HAS AN IMPRESSIVE RECORD OF SCHOLARLY PUBLICATION AND TRANSLATIONAL RESEARCH SUCCESS, INCLUDING DEVELOPMENT OF THE FIRST HYBRID PET/CT SCANNER AND THE AMYLOID IMAGING AGENTS [11C]PITTSBURGH-COMPOUND B (PIB) AND THE FDA- APPROVED [18F]FLUTEMETAMOL (VIZAMYL™) USED WORLDWIDE IN ALZHEIMER’S DISEASE RESEARCH, CLINICAL TRIALS, AND DIAGNOSTICS. THE REQUESTED UNEUROEXPLORER WILL REPLACE A LEGACY SIEMENS ECAT EXACT HR+ PET SCANNER WHICH WAS INSTALLED IN 1996 AND DECLARED END-OF-LIFE BY THE MANUFACTURER IN 2013. THE LIMITED SERVICEABILITY AND INFERIOR PERFORMANCE OF THE HR+ HAS BEGUN TO IMPACT PRODUCTIVITY FOR THE 10 MAJOR AND 5 OTHER USER PROJECTS DESCRIBED IN THIS PROPOSAL. ACCESS TO A MODERN, HIGH-PERFORMANCE BRAIN PET/CT SCANNER SUCH AS THE UNEUROEXPLORER, OFFERING IMPROVED SIGNAL-TO-NOISE CHARACTERISTICS, STATISTICAL QUALITY, AND QUANTITATIVE ACCURACY, IS CRITICAL TO THE CONTINUED SUCCESS OF THESE PROJECTS. AS THE ONLY COMMERCIALLY AVAILABLE PET/CT SCANNER DESIGNED EXPRESSLY FOR HUMAN BRAIN IMAGING, THE UNEUROEXPLORER IS WELL SUITED TO THE PREDOMINANTLY (~85%) NEUROSCIENCE PET IMAGING RESEARCH ENVIRONMENT OF THE UPPC. WITH A SMALL PATIENT BORE (50 CM) AND A LARGE AXIAL FOV (49.5 CM), THIS SCANNER PROVIDES SUPERIOR SOLID ANGLE COVERAGE YIELDING VERY HIGH 3D SYSTEM SENSITIVITY (46 KCPS/MBQ). A UNIQUE DETECTOR DESIGN INCLUDES DEPTH-OF-INTERACTION ENCODING AND OFFERS UNPARALLELED MAXIMUM INTRINSIC SPATIAL RESOLUTION (1.7 MM FWHM IN-PLANE) AND COUNT-RATE PERFORMANCE (PEAK NOISE EQUIVALENT COUNT RATE 1,310 KCPS @ 58 KBQ) FAR SURPASSING ANY OTHER COMMERCIALLY AVAILABLE PET/CT AND YIELDING BRAIN IMAGES WITH UNMATCHED FIDELITY. ANOTHER UNIQUE FEATURE IS A FULLY INTEGRATED 3D CAMERA SYSTEM FOR EVENT-BASED MOTION CORRECTION OF PET EMISSION DATA. THE UNEUROEXPLORER WILL BE OPERATED BY THE UPPC IN TANDEM WITH AN EXISTING SIEMENS BIOGRAPH MCT FLOW WHOLE-BODY PET/CT SCANNER INSTALLED IN 2014. NIH-FUNDED NEUROIMAGING RESEARCH WILL BE MIGRATED FROM THE MCT TO THE UNEUROEXPLORER, ENABLING COMMITMENT OF THE MCT TO THE GROWING BODY IMAGING COMPONENT OF FUNDED RESEARCH, AS WELL AS TO NEUROSCIENCE RESEARCH THAT IS NOT NIH-FUNDED. CURRENTLY THESE PROJECTS COMPETE WITH MAJOR USER PROJECTS FOR MCT SCANNER TIME, CREATING LONG SCHEDULING DELAYS. AVAILABILITY OF TWO RESEARCH-DEDICATED PET/CT SCANNERS IS CRITICAL FOR LEVERAGING THE UPPC’S PET RADIOPHARMACEUTICAL PRODUCTION CAPACITY AND MEETING THE PET SCANNER DEMANDS OF ITS USER BASE. THE REPLACEMENT OF UPPC’S LEGACY HR+ SCANNER WITH THE UNEUROEXPLORER WILL RESULT IN A GREATER STUDY OUTPUT AND WILL SUPPORT CONTINUED EXPANSION OF THE SCOPE OF PET IMAGING RESEARCH CONDUCTED AT THE INSTITUTION. | $2,000,000 |
| Department of Health and Human Services | THE HYPERTENSION TOOLKIT: AN ADAPTIVE MOBILE HEALTH BLOOD PRESSURE INTERVENTION - HYPERTENSION (HTN) IS THE FOREMOST MODIFIABLE CAUSE OF CARDIOVASCULAR MORBIDITY AND MORTALITY. WE HAVE PARTNERED WITH COMMUNITY-BASED AND FEDERALLY QUALIFIED HEALTH CENTERS TO DEVELOP A RANDOMIZED CLINICAL TRIAL TO ADDRESS BLOOD PRESSURE (BP) TREATMENT, MANAGEMENT, AND CONTROL IN LIMITED-RESOURCE PRIMARY CARE SETTINGS. OUR MULTILEVEL HTN TOOLKIT PROVIDES THEORY-INFORMED CHRONIC DISEASE SELF-MANAGEMENT (CDSM), AND CONSISTS OF HTN EDUCATION, GUIDANCE ON NON-PHARMACOLOGIC AND LIFESTYLE APPROACHES, SUPPORT FOR LONGITUDINAL HOME- BLOOD PRESSURE MONITORING (HBPM), AND ENHANCED HTN TREATMENT. ALL TRIAL PARTICIPANTS (N=378) RECEIVE HBPM AND A CDSM WORKBOOK. INTERVENTION PARTICIPANTS RECEIVE OUR VALIDATED HTN VIRTUAL COACH THAT GUIDES CDSM, CONNECTS WITH HBPM RESULTS, AND FACILITATES SELF-EFFICACY. THE STUDY EMPLOYS A SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART) DESIGN, SUCH THAT NON-RESPONDERS (INTERVENTION OR ENHANCED USUAL CARE PARTICIPANTS WITH SYSTOLIC BP≥130 MM HG) AT EITHER A 2- OR 4-MONTH HOME-SUPERVISED BP VISIT ARE RE-RANDOMIZED TO RECEIVE AUGMENTED HTN TOOLKIT TACTICS: (1) MODEST AUGMENTATION, OUR TEXT-BASED DIGITAL HEALTH PROGRAM, DEMONSTRATED TO SUPPORT HBPM; OR (2) VIGOROUS AUGMENTATION, TEXT-BASED DIGITAL HEALTH PLUS PHARMACIST CO- MANAGEMENT OF HTN THERAPY. WE HAVE DEVELOPED A COMMUNITY ENGAGEMENT COLLABORATIVE (CEC) IN CONCERT WITH OUR PARTNER CLINICS TO GUIDE THE STUDY DESIGN AND TOOLKIT ELEMENTS. IN THE R61 PHASE, OUR CEC WILL REVIEW STUDY MATERIALS; WE WILL TAILOR OUR VIRTUAL AGENT, GUIDED BY THE CEC AND PARTNER CLINICS; COORDINATE WITH THE CLINICS; AND LAUNCH THE TRIAL. AS R33 PHASE AIMS, WE WILL: (AIM 1) DETERMINE THE 6-MONTH EFFECT OF THE VIRTUAL AGENT AS OUR PRIMARY OUTCOME. AS SECONDARY OUTCOMES WE WILL DETERMINE (A) THE OPTIMAL AUGMENTATION TACTIC (MODEST [TEXTS] VS VIGOROUS [TEXTS PLUS PHARMACIST CO-MANAGEMENT]) TO ADDRESS SBP NON-RESPONSE AND (B) THE EFFECTS OF THE HTN VIRTUAL AGENT AND AUGMENTATION TACTICS AT 12 MONTHS. (AIM 2) QUANTIFY THE BUDGET IMPACT AND COST-EFFECTIVENESS OF THE HTN TOOLKIT AND AUGMENTATION TACTICS. WE WILL APPLY THE HIGHLY VALIDATED BP- CARDIOVASCULAR DISEASE POLICY MODEL TO ESTIMATE THE 1- AND 10-YEAR EFFECTS ON BP CONTROL, EVENTS PREVENTED, PROGRAM AND HEALTH CARE COSTS, AND QUALITY-ADJUSTED LIFE YEARS. (AIM 3) EVALUATE THE IMPLEMENTATION PROCESS OF THE HTN TOOLKIT WITH QUALITATIVE ASSESSMENTS OF PARTICIPANTS AND PARTNER CLINIC PROVIDERS AND LEADERSHIP AS GUIDED BY THE CONSOLIDATED FRAMEWORK FOR IMPLEMENTATION RESEARCH 2.0. WE WILL CONDUCT AN EXPLANATORY SEQUENTIAL MIXED METHODS DESIGN TO IDENTIFY POTENTIAL MECHANISMS OF EFFECT OF THE HTN TOOLKIT AND ITS BARRIERS, FACILITATORS, AND CONTEXT. EXPECTED RESULTS: OUR MULTIDISCIPLINARY TEAM IN CONCERT WITH OUR CEC AND PARTNER CLINICS HAS EXPERTISE IN HBPM APPLICATION, CLINICAL TRIALS, SMART DESIGN, BUDGET IMPACT FOR HTN INTERVENTIONS, COMMUNITY ENGAGEMENT, AND IMPLEMENTATION. WE WILL EVALUATE A SCALABLE, PATIENT-CENTERED INTERVENTION TO IMPROVE HTN CONTROL IN RESOURCE-LIMITED SETTINGS SUCH AS OUR PARTNER CLINICS. IF PROVEN SUCCESSFUL, THIS INTERVENTION CAN BE BROADLY DISSEMINATED TO IMPROVE HTN CARE AND MANAGEMENT. | $1,019,556 |